Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VX-828/deutivacaftor with and without tezacaftor in adults with cystic fibrosis
2025-523400-72-00Phase 2Authorised
- Sponsor
- Vertex Pharmaceuticals
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 2, randomised, double-blind trial of VX-828, deutivacaftor and tezacaftor in cystic fibrosis (CF) (3 arms), sponsored by Vertex Pharmaceuticals. Primary endpoints: Safety and tolerability and Absolute change in sweat chloride. Planned start May 2026; status: authorised.
02
Drugs
VX-828deutivacaftortezacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2025-523400-72-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523400-72-00.